» Articles » PMID: 22802689

New Chitosan Nanobubbles for Ultrasound-mediated Gene Delivery: Preparation and in Vitro Characterization

Overview
Publisher Dove Medical Press
Specialty Biotechnology
Date 2012 Jul 18
PMID 22802689
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The development of nonviral gene delivery systems is one of the most intriguing topics in nanomedicine. However, despite the advances made in recent years, several key issues remain unsettled. One of the main problems relates to the difficulty in designing nanodevices for targeted delivery of genes and other drugs to specific anatomic sites. In this study, we describe the development of a novel chitosan nanobubble-based gene delivery system for ultrasound-triggered release.

Methods And Results: Chitosan was selected for the nanobubble shell because of its low toxicity, low immunogenicity, and excellent biocompatibility, while the core consisted of perfluoropentane. DNA-loaded chitosan nanobubbles were formed with a mean diameter of less than 300 nm and a positive surface charge. Transmission electron microscopic analysis confirmed composition of the core-shell structure. The ability of the chitosan nanobubbles to complex with and protect DNA was confirmed by agarose gel assay. Chitosan nanobubbles were found to be stable following insonation (2.5 MHz) for up to 3 minutes at 37°C. DNA release was evaluated in vitro in both the presence and absence of ultrasound. The release of chitosan nanobubble-bound plasmid DNA occurred after just one minute of insonation. In vitro transfection experiments were performed by exposing adherent COS7 cells to ultrasound in the presence of different concentrations of plasmid DNA-loaded nanobubbles. In the absence of ultrasound, nanobubbles failed to trigger transfection at all concentrations tested. In contrast, 30 seconds of ultrasound promoted a moderate degree of transfection. Cell viability experiments demonstrated that neither ultrasound nor the nanobubbles affected cell viability under these experimental conditions.

Conclusion: Based on these results, chitosan nanobubbles have the potential to be promising tools for ultrasound-mediated DNA delivery.

Citing Articles

The anti-glypican 1 AT101 antibody as targeting agent to effectively deliver chitosan nanobubbles to glioblastoma cells.

Di Cintio F, Argenziano M, Scomparin A, Capolla S, Busato D, Steffe A Nanomedicine (Lond). 2024; 20(1):23-36.

PMID: 39620421 PMC: 11703443. DOI: 10.1080/17435889.2024.2434451.


Strategies, Challenges, and Prospects of Nanoparticles in Gynecological Malignancies.

Zhang Y, Tian J ACS Omega. 2024; 9(36):37459-37504.

PMID: 39281920 PMC: 11391544. DOI: 10.1021/acsomega.4c04573.


Radiation combined with ultrasound and microbubbles: A potential novel strategy for cancer treatment.

Sharma D, Xuan Leong K, Palhares D, Czarnota G Z Med Phys. 2023; 33(3):407-426.

PMID: 37586962 PMC: 10517408. DOI: 10.1016/j.zemedi.2023.04.007.


Targeted chitosan nanobubbles as a strategy to down-regulate microRNA-17 into B-cell lymphoma models.

Capolla S, Argenziano M, Bozzer S, DAgaro T, Bittolo T, De Leo L Front Immunol. 2023; 14:1200310.

PMID: 37359561 PMC: 10285521. DOI: 10.3389/fimmu.2023.1200310.


Plasminogen activator-coated nanobubbles targeting cellbound β2-glycoprotein I as a novel thrombus-specific thrombolytic strategy.

Macor P, Durigutto P, Argenziano M, Smith-Jackson K, Capolla S, Di Leonardo V Haematologica. 2022; 108(7):1861-1872.

PMID: 36172817 PMC: 10316273. DOI: 10.3324/haematol.2022.281505.


References
1.
Horie S, Watanabe Y, Chen R, Mori S, Matsumura Y, Kodama T . Development of localized gene delivery using a dual-intensity ultrasound system in the bladder. Ultrasound Med Biol. 2010; 36(11):1867-75. DOI: 10.1016/j.ultrasmedbio.2010.07.015. View

2.
Iyer A, Khaled G, Fang J, Maeda H . Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006; 11(17-18):812-8. DOI: 10.1016/j.drudis.2006.07.005. View

3.
Sirsi S, Borden M . Microbubble Compositions, Properties and Biomedical Applications. Bubble Sci Eng Technol. 2010; 1(1-2):3-17. PMC: 2889676. DOI: 10.1179/175889709X446507. View

4.
Patil S, Rhodes D, Burgess D . DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J. 2005; 7(1):E61-77. PMC: 2751499. DOI: 10.1208/aapsj070109. View

5.
Baldrick P . The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol. 2009; 56(3):290-9. DOI: 10.1016/j.yrtph.2009.09.015. View